Using machine learning to analyse the genetic factors behind early clinical trial termination, researchers find a link between genetic evidence and trial outcome.
SCIENCE & TECHNOLOGY2024
research-highlightsscience-technology
MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative’s collaborative efforts in drug discovery.
EMBL ANNOUNCEMENTS2024
announcementsembl-announcements
Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
EMBL ANNOUNCEMENTS2023
announcementsembl-announcements
Researchers create a network of interacting proteins – or interactome – to aid drug discovery.
2023
research-highlightsscience
Open Targets is using artificial intelligence and machine learning to identify and prioritise drug targets.
SCIENCE & TECHNOLOGY2023
sciencescience-technologytechnology-and-innovation
Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium.
2022
announcementsscience
Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
CONNECTIONS2022
announcementsconnectionsscience
Ian Dunham walks us through his career so far including working on the human genome project, seeing his work on the cover of Nature and his current role as Director of Open Targets.
LAB MATTERSPEOPLE & PERSPECTIVES2021
lab-matterspeople-perspectives
Researchers establish a framework for identifying new drugs capable of exploiting a cell’s own machinery.
SCIENCE & TECHNOLOGY2021
sciencescience-technology
No matching posts found